drugset / Trial / NCT05973370

Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

NCT05973370

Phase 2 Completed 60 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the potential therapeutic effects of the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatment for rheumatoid arthritis patients with variant disease activity.

Timeline

Start
2023-05-01
Primary completion
2023-11-30
Completion
2024-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ursodeoxycholic Acid Small molecule 500 mg

Indications